New acetylcholinesterase inhibitors for Alzheimer's disease
- PMID: 22216416
- PMCID: PMC3246720
- DOI: 10.1155/2012/728983
New acetylcholinesterase inhibitors for Alzheimer's disease
Abstract
Acetylcholinesterase (AChE) remains a highly viable target for the symptomatic improvement in Alzheimer's disease (AD) because cholinergic deficit is a consistent and early finding in AD. The treatment approach of inhibiting peripheral AchE for myasthenia gravis had effectively proven that AchE inhibition was a reachable therapeutic target. Subsequently tacrine, donepezil, rivastigmine, and galantamine were developed and approved for the symptomatic treatment of AD. Since then, multiple cholinesterase inhibitors (ChEI) continue to be developed. These include newer ChEIs, naturally derived ChEIs, hybrids, and synthetic analogues. In this paper, we summarize the different types of ChEIs in development and their respective mechanisms of actions. This pharmacological approach continues to be active with many promising compounds.
Similar articles
-
Cholinesterase Inhibitors for Alzheimer's Disease: Multitargeting Strategy Based on Anti-Alzheimer's Drugs Repositioning.Curr Pharm Des. 2019;25(33):3519-3535. doi: 10.2174/1381612825666191008103141. Curr Pharm Des. 2019. PMID: 31593530 Review.
-
Pharmacodynamics of cholinesterase inhibitors suggests add-on therapy with a low-dose carbamylating inhibitor in patients on long-term treatment with rapidly reversible inhibitors.J Alzheimers Dis. 2014;39(2):423-40. doi: 10.3233/JAD-130845. J Alzheimers Dis. 2014. PMID: 24217282 Clinical Trial.
-
Anti-Cholinesterase Combination Drug Therapy as a Potential Treatment for Alzheimer's Disease.Brain Sci. 2021 Feb 2;11(2):184. doi: 10.3390/brainsci11020184. Brain Sci. 2021. PMID: 33540879 Free PMC article.
-
Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.Drug Saf. 1998 Dec;19(6):465-80. doi: 10.2165/00002018-199819060-00004. Drug Saf. 1998. PMID: 9880090 Review.
-
The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.Int J Clin Pract Suppl. 2002 Jun;(127):45-63. Int J Clin Pract Suppl. 2002. PMID: 12139367 Review.
Cited by
-
Comparative risk of cardiac arrhythmias associated with acetylcholinesterase inhibitors used in treatment of dementias - A narrative review.Pharmacol Res Perspect. 2020 Aug;8(4):e00622. doi: 10.1002/prp2.622. Pharmacol Res Perspect. 2020. PMID: 32691984 Free PMC article. Review.
-
Investigation of therapeutic potential of cerium oxide nanoparticles in Alzheimer's disease using transgenic Drosophila.3 Biotech. 2021 Apr;11(4):159. doi: 10.1007/s13205-021-02706-x. Epub 2021 Mar 6. 3 Biotech. 2021. PMID: 33758737 Free PMC article.
-
Investigating the optimistic in-vitro and in-vivo therapeutic effects of wild grape: Vitis jacqumantii R. Parker.Heliyon. 2024 Nov 30;10(23):e40804. doi: 10.1016/j.heliyon.2024.e40804. eCollection 2024 Dec 15. Heliyon. 2024. PMID: 39698089 Free PMC article.
-
Curcumin-Loaded Mesoporous Silica Nanoparticles Dispersed in Thermo-Responsive Hydrogel as Potential Alzheimer Disease Therapy.Pharmaceutics. 2022 Sep 19;14(9):1976. doi: 10.3390/pharmaceutics14091976. Pharmaceutics. 2022. PMID: 36145723 Free PMC article.
-
Function and clinical meaningfulness of treatments for mild Alzheimer's disease.Alzheimers Dement (Amst). 2016 Mar 10;2:105-12. doi: 10.1016/j.dadm.2016.02.006. eCollection 2016. Alzheimers Dement (Amst). 2016. PMID: 27239541 Free PMC article.
References
-
- Orhan G, Orhan I, Öztekin-Subutay N, Ak F, Şener B. Contemporary anticholinesterase pharmaceuticals of natural origin and their synthetic analogues for the treatment of Alzheimer’s disease. Recent Patents on CNS Drug Discovery. 2009;4(1):43–51. - PubMed
-
- Tumiatti V, Minarini A, Bolognesi ML, Milelli A, Rosini M, Melchiorre C. Tacrine derivatives and Alzheimer’s disease. Current Medicinal Chemistry. 2010;17(17):1825–1838. - PubMed
-
- Fernández-Bachiller MI, Pérez C, González-Muñoz GC, et al. Novel tacrine-8-hydroxyquinoline hybrids as multifunctional agents for the treatment of Alzheimers disease, with neuroprotective, cholinergic, antioxidant, and copper-complexing properties. Journal of Medicinal Chemistry. 2010;53(13):4927–4937. - PubMed
-
- Tacrine. Drugs in Clinical Trials. Alzheimer Research Forum, http://www.alzforum.org/drg/drc/detail.asp?id=90.
-
- Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Archives of Internal Medicine. 1998;158(9):1021–1031. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources